Program Status
Active, not recruitingPhase
Phase 1Prior Immunotherapy Allowed
YesCRC-directed Trial
NoDrugs
BMS-986258, Nivolumab, rHuPH20Tags
MSS/ MMRpComments
BMS-986258 (TIM-3 antibody) + nivolumab (anti PD-1)
Location | Location Status |
---|---|
United States | |
Local Institution - 0004 Los Angeles, California 90033 |
Active, not recruiting |
Local Institution - 0006 Los Angeles, California 90033 |
Active, not recruiting |
Local Institution - 0007 Aurora, Colorado 80045 |
Active, not recruiting |
University Of Iowa Hospitals And Clinics Iowa City, Iowa 52242 |
Active, not recruiting |
Local Institution - 0018 Ann Arbor, Michigan 48109-5912 |
Active, not recruiting |
Local Institution - 0010 Grand Rapids, Michigan 49546 |
Active, not recruiting |
Local Institution - 0012 Lebanon, New Hampshire 03756 |
Active, not recruiting |
Local Institution - 0016 Cincinnati, Ohio 45267 |
Active, not recruiting |
Local Institution - 0005 Pittsburgh, Pennsylvania 15232 |
Active, not recruiting |
Local Institution - 0002 Germantown, Tennessee 38138 |
Active, not recruiting |
Australia | |
Local Institution - 0013 Westmead, New South Wales 2145 |
Active, not recruiting |
Local Institution - 0015 Melbourne, Victoria 3084 |
Active, not recruiting |
Canada | |
Local Institution - 0014 Edmonton, Alberta T6X 1E8 |
Active, not recruiting |
Local Institution - 0019 Vancouver, British Columbia V5Z 4E6 |
Active, not recruiting |
Japan | |
Local Institution - 0009 Kobe-shi, Hyogo 6500017 |
Active, not recruiting |
Local Institution - 0008 Chuo-ku, Tokyo 1040045 |
Active, not recruiting |
Inclusion Criteria
Inclusion Criteria:
Histologic confirmation of one of the 5 tumors [renal cell carcinoma (RCC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC)] (metastatic, recurrent, and/or unresectable), with measurable disease per response evaluation criteria in solid tumors v1.1 (RECIST v1.1)
Eastern Cooperative Oncology Group Performance Status of 0 or 1
Participants must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies
Women must agree to follow specific methods of contraception, if applicable
Exclusion Criteria
Exclusion Criteria:
Active, known or suspected autoimmune disease
Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy
Other active malignancy requiring concurrent intervention
Other protocol-defined inclusion/exclusion criteria apply